Benralizumab Trial Correction
Cross-source consensus on Benralizumab Trial Correction from 1 sources and 6 claims.
1 sources · 6 claims
Background
Evidence quality
Other
Other
Other
Highlighted claims
- The article is an author correction for a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- The original benralizumab study was published in Nature Medicine on March 31, 2026. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- The corrections affect fatigue scores and baseline patient characteristics in multiple data tables. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- The corrected data have been updated in both the HTML and PDF versions of the article. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- The article reports corrections to data errors in a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- The corrected data affect fatigue scores and baseline patient characteristics across multiple tables. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals